Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

284
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
284
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

306
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
306

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PERIVASCULAR MULTIFOCAL CHOROIDITIS WITH PANUVEITIS: Clinical and Multimodal Imaging Features.

Retina (Philadelphia, Pa.)·2026
Same author

Nucleic acid-based therapeutics to restore joint homeostasis in age-related and post-traumatic arthritis.

npj biomedical innovations·2026
Same author

VKH-Like Syndrome in a Patient on Tofacitinib.

Journal of vitreoretinal diseases·2026
Same author

Effect of the COVID-19 Pandemic on Presentation and Outcomes of Pars Plana Vitrectomy for Complications of Diabetic Retinopathy Within a County System.

Journal of vitreoretinal diseases·2026
Same author

Retinal Vasculitis and Stroke Risk in Patients with Systemic Lupus Erythematosus.

Ocular immunology and inflammation·2025
Same author

EFFICACY AND SAFETY OF SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE IN MIXED ETIOLOGY NONINFECTIOUS CYSTOID MACULAR EDEMA.

Retina (Philadelphia, Pa.)·2025

Related Experiment Video

Updated: Nov 10, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.9K

Posterior Uveitis Associated with Cemiplimab.

Eliot R Dow1, Kirk Hou1, Susan Ransome1

  • 1Stein Eye Institute, David Geffen of Medicine at UCLA, Los Angeles, California, USA.

Ocular Immunology and Inflammation
|April 1, 2021
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICPIs) like cemiplimab can cause uveitis, an inflammatory eye condition. Early detection and treatment with steroids, along with stopping the ICPI, can effectively manage this side effect.

Keywords:
Immune checkpoint inhibitorLibtayoPD-1 inhibitorcemiplimabcemiplimab-rwlcphlebitisuveitisvasculitis

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.5K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

611

Related Experiment Videos

Last Updated: Nov 10, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.9K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.5K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

611

Area of Science:

  • Oncology
  • Immunology
  • Ophthalmology

Background:

  • Immune checkpoint inhibitors (ICPIs) are a class of oncologic immunotherapies that disinhibit T-cells to target tumor cells.
  • Cemiplimab (Libtayo®) is a recently FDA-approved ICPI.
  • ICPIs are associated with immune-related adverse events, including uveitis.

Observation:

  • A case report details a 63-year-old man with metastatic squamous cell carcinoma.
  • The patient developed blurry vision three months into cemiplimab treatment.
  • Ophthalmological examination revealed posterior uveitis with retinal vasculitis.

Findings:

  • Cemiplimab treatment was discontinued.
  • The patient received local and systemic steroid therapy.
  • Posterior uveitis with retinal vasculitis was successfully controlled.

Implications:

  • Uveitis is a potential adverse event associated with cemiplimab, similar to other ICPIs.
  • Management of cemiplimab-induced posterior uveitis may necessitate medication cessation and intensive steroid treatment.
  • This case highlights the importance of monitoring for ocular side effects in patients receiving cemiplimab.